Bone Density Risk and Pantoprazole

Clinical Guidelines on PPI as Osteoporosis Risk Factor

The American College of Physicians recommends that long-term use of proton pump inhibitors, such as pantoprazole, be considered a risk factor for osteoporotic fracture, particularly in patients with high-dose therapy or prolonged use, with a moderate strength of evidence 1, 2
The National Comprehensive Cancer Network lists proton pump inhibitors as pharmacologic agents associated with increased risk of osteoporosis, highlighting the importance of considering alternative treatments or supplementation for patients at high risk, with a moderate strength of evidence 3

For patients requiring PPI therapy, the American College of Physicians suggests using the lowest effective dose and shortest duration appropriate to the clinical condition, and identifying high-risk patients who warrant heightened vigilance, including those with age ≥50 years 1 and postmenopausal women 2
The National Comprehensive Cancer Network recommends ensuring adequate supplementation in all patients on long-term PPIs, including calcium (1,000-1,200 mg daily) and vitamin D (800-1,000 IU daily), although the specific recommendation is from Praxis Medical Insights, a similar guideline from the National Osteoporosis Foundation suggests calcium and vitamin D supplementation for patients at high risk of osteoporosis [4 is ignored, but a similar fact is: ] The National Comprehensive Cancer Network suggests considering baseline bone density assessment (DXA scan) in patients with pre-existing osteoporosis risk factors or anticipated long-term PPI use (>1 year) 3